Revolution Medicines (RVMD) Gains from Investment Securities (2018 - 2026)

Revolution Medicines' Gains from Investment Securities history runs 9 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 180.04% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (down 29.78% YoY), while the FY2025 annual figure was $18.0 million, up 28.69% from the prior year.
• Gains from Investment Securities was $2.0 million for Q1 2026 at Revolution Medicines, up from -$22.5 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $13.8 million in Q2 2024 to a low of -$22.5 million in Q4 2025.
• Historically, Gains from Investment Securities has averaged $1.5 million across 5 years, with a median of $1.7 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Gains from Investment Securities jumped 3572.12% in 2022, then tumbled 2689.81% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $3.8 million in 2022, then slumped by 42.26% to $2.2 million in 2023, then tumbled by 136.51% to -$805000.0 in 2024, then sank by 2689.81% to -$22.5 million in 2025, then jumped by 108.69% to $2.0 million in 2026.
• The last three Gains from Investment Securities figures came in at $2.0 million (Q1 2026), -$22.5 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.